List of Twyneo drug patents

Twyneo is owned by Galderma Labs Lp.

Twyneo contains Benzoyl Peroxide; Tretinoin.

Twyneo has a total of 5 drug patents out of which 0 drug patents have expired.

Twyneo was authorised for market use on 26 July, 2021.

Twyneo is available in cream;topical dosage forms.

Twyneo can be used as topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older.

The generics of Twyneo are possible to be released after 12 July, 2038.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8617580 GALDERMA LABS LP Compositions for topical application comprising a peroxide and retinoid
Feb, 2028

(4 years from now)

US9868103 GALDERMA LABS LP Metal oxide coating of water insoluble ingredients
Aug, 2028

(5 years from now)

US10653899 GALDERMA LABS LP Core stabilized microcapsules, method of their preparation and uses thereof
Dec, 2030

(7 years from now)

US11071878 GALDERMA LABS LP Core stabilized microcapsules, method of their preparation and uses thereof
Dec, 2030

(7 years from now)

US10420743 GALDERMA LABS LP Methods and compositions for the treatment of acne
Jul, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Combination (NC) Jul 26, 2024

Drugs and Companies using BENZOYL PEROXIDE; TRETINOIN ingredient

Market Authorisation Date: 26 July, 2021

Treatment: Topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older

Dosage: CREAM;TOPICAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in